Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Maze Therapeutics, Inc. (MAZE) since 2025 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Maze Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1842295.
Total stock buying since 2025: $0.
Total stock sales since 2025: $8,412,513.
Total stock option exercises since 2025: $2,051,832.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 64,413 | $2,551,687 | 64,413 | $671,182 |
| 2025 | 0 | $0 | 153,244 | $5,860,826 | 132,500 | $1,380,650 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-01 | 0 | $0 | 64,413 | $2,551,687 | 64,413 | $671,182 |
| 2025-12 | 0 | $0 | 132,500 | $5,396,783 | 132,500 | $1,380,650 |
| 2025-09 | 0 | $0 | 20,744 | $464,043 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-01-07 | Bernstein Harold (President, R&D & CMO) | Sale | 25,156 | 40.20 | 1,011,296 |
| 2026-01-07 | Bernstein Harold (President, R&D & CMO) | Option Ex | 25,156 | 10.42 | 262,125 |
| 2026-01-07 | Sohn Catherine A. | Sale | 26,920 | 39.11 | 1,052,787 |
| 2026-01-07 | Sohn Catherine A. | Option Ex | 26,920 | 10.42 | 280,506 |
| 2026-01-06 | Sohn Catherine A. | Sale | 2,493 | 38.62 | 96,269 |
| 2026-01-06 | Sohn Catherine A. | Option Ex | 2,493 | 10.42 | 25,977 |
| 2026-01-05 | Bernstein Harold (President, R&D & CMO) | Sale | 412 | 40.00 | 16,480 |
| 2026-01-05 | Bernstein Harold (President, R&D & CMO) | Option Ex | 412 | 10.42 | 4,293 |
| 2026-01-02 | Bachrodt Amy (SVP, Finance) | Sale | 5,000 | 39.13 | 195,670 |
| 2026-01-02 | Bachrodt Amy (SVP, Finance) | Option Ex | 5,000 | 10.42 | 52,100 |
| 2026-01-02 | Bernstein Harold (President, R&D & CMO) | Sale | 4,432 | 40.43 | 179,185 |
| 2026-01-02 | Bernstein Harold (President, R&D & CMO) | Option Ex | 4,432 | 10.42 | 46,181 |
| 2025-12-30 | Bachrodt Amy (SVP, Finance) | Sale | 5,000 | 40.08 | 200,405 |
| 2025-12-30 | Bachrodt Amy (SVP, Finance) | Option Ex | 5,000 | 10.42 | 52,100 |
| 2025-12-30 | Dandekar Atul (CSBO) | Sale | 100 | 40.36 | 4,036 |
| 2025-12-30 | Dandekar Atul (CSBO) | Option Ex | 100 | 10.42 | 1,042 |
| 2025-12-29 | Bachrodt Amy (SVP, Finance) | Sale | 10,000 | 40.85 | 408,489 |
| 2025-12-29 | Bachrodt Amy (SVP, Finance) | Option Ex | 10,000 | 10.42 | 104,200 |
| 2025-12-29 | Bernstein Harold (President, R&D & CMO) | Sale | 45,000 | 40.63 | 1,828,485 |
| 2025-12-29 | Bernstein Harold (President, R&D & CMO) | Option Ex | 45,000 | 10.42 | 468,900 |
| 2025-12-29 | Dandekar Atul (CSBO) | Sale | 72,400 | 40.82 | 2,955,368 |
| 2025-12-29 | Dandekar Atul (CSBO) | Option Ex | 72,400 | 10.42 | 754,408 |
| 2025-09-15 | Scheller Richard H | Sale | 20,744 | 22.37 | 464,043 |
Insider trading activities including stock purchases, stock sales, and option exercises of MAZE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Maze Therapeutics, Inc. (symbol MAZE, CIK number 1842295) see the Securities and Exchange Commission (SEC) website.